CN116694570A - 一种利用自体肿瘤细胞及培养物来快速扩增培养TILs的方法及应用 - Google Patents
一种利用自体肿瘤细胞及培养物来快速扩增培养TILs的方法及应用 Download PDFInfo
- Publication number
- CN116694570A CN116694570A CN202310681997.0A CN202310681997A CN116694570A CN 116694570 A CN116694570 A CN 116694570A CN 202310681997 A CN202310681997 A CN 202310681997A CN 116694570 A CN116694570 A CN 116694570A
- Authority
- CN
- China
- Prior art keywords
- tumor
- organoid
- supernatant
- cells
- infiltrating lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 title claims abstract description 133
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 39
- 230000003321 amplification Effects 0.000 title abstract description 15
- 238000003199 nucleic acid amplification method Methods 0.000 title abstract description 15
- 210000002220 organoid Anatomy 0.000 claims abstract description 86
- 239000006228 supernatant Substances 0.000 claims abstract description 65
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 61
- 210000004027 cell Anatomy 0.000 claims abstract description 33
- 238000012258 culturing Methods 0.000 claims abstract description 25
- 239000012530 fluid Substances 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 23
- 239000001963 growth medium Substances 0.000 claims description 16
- 238000004113 cell culture Methods 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 230000001079 digestive effect Effects 0.000 claims description 9
- 102000029816 Collagenase Human genes 0.000 claims description 8
- 108060005980 Collagenase Proteins 0.000 claims description 8
- 229960002424 collagenase Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 108010084091 heregulin beta1 Proteins 0.000 claims description 3
- 108010082117 matrigel Proteins 0.000 claims description 3
- 102000045246 noggin Human genes 0.000 claims description 3
- 108700007229 noggin Proteins 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 239000012679 serum free medium Substances 0.000 claims description 3
- 239000004017 serum-free culture medium Substances 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- -1 R-Spondin Proteins 0.000 claims 1
- 239000012531 culture fluid Substances 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 71
- 108010060889 Toll-like receptor 1 Proteins 0.000 description 71
- 239000002609 medium Substances 0.000 description 12
- 108010002350 Interleukin-2 Proteins 0.000 description 11
- 230000002147 killing effect Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 108010074108 interleukin-21 Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 102000004864 Fibroblast growth factor 10 Human genes 0.000 description 3
- 108010002335 Interleukin-9 Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- NWNOWCGAHDFNFJ-RUCXOUQFSA-N (2s)-2,5-bis(azanyl)-5-oxidanylidene-pentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CCC(N)=O NWNOWCGAHDFNFJ-RUCXOUQFSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 102000055650 human NRG1 Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310681997.0A CN116694570A (zh) | 2023-06-09 | 2023-06-09 | 一种利用自体肿瘤细胞及培养物来快速扩增培养TILs的方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310681997.0A CN116694570A (zh) | 2023-06-09 | 2023-06-09 | 一种利用自体肿瘤细胞及培养物来快速扩增培养TILs的方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116694570A true CN116694570A (zh) | 2023-09-05 |
Family
ID=87844586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310681997.0A Pending CN116694570A (zh) | 2023-06-09 | 2023-06-09 | 一种利用自体肿瘤细胞及培养物来快速扩增培养TILs的方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116694570A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117511880A (zh) * | 2024-01-08 | 2024-02-06 | 北京大橡科技有限公司 | 肿瘤体外原位模型的构建方法、培养基及体外应用 |
-
2023
- 2023-06-09 CN CN202310681997.0A patent/CN116694570A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117511880A (zh) * | 2024-01-08 | 2024-02-06 | 北京大橡科技有限公司 | 肿瘤体外原位模型的构建方法、培养基及体外应用 |
CN117511880B (zh) * | 2024-01-08 | 2024-04-19 | 北京大橡科技有限公司 | 肿瘤体外原位模型的构建方法、培养基及体外应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU500561B1 (en) | In vitro construction method and use of liver organoids | |
JP4336821B2 (ja) | 哺乳動物の骨髄細胞または臍帯血由来細胞と脂肪組織を利用した心筋細胞の誘導 | |
CN105683359B (zh) | 将从间充质干细胞诱导的多能干细胞分化为肝细胞的方法 | |
CN105683360B (zh) | 将从间充质干细胞诱导的多能干细胞分化为神经细胞的方法 | |
CN105705632B (zh) | 将从间充质干细胞诱导的多能干细胞分化为软骨细胞的方法 | |
CN108504625B (zh) | 一种小鼠成纤维细胞及其用途 | |
CN116694570A (zh) | 一种利用自体肿瘤细胞及培养物来快速扩增培养TILs的方法及应用 | |
CN111344392B (zh) | 一种细胞诱导的方法 | |
KR20120006386A (ko) | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 | |
US11186828B2 (en) | Method of making human cells expressing OCT4, SOX2, and Nanog using an Ecklonia cava extract | |
CN111235100B (zh) | 一种人脐带血间充质干细胞的培养方法 | |
CN105683358B (zh) | 将从间充质干细胞诱导的多能干细胞分化为脂肪细胞的方法 | |
CN105705631B (zh) | 将从间充质干细胞诱导的多能干细胞分化为造骨细胞的方法 | |
CN115820548A (zh) | 一种动物组织来源的凋亡囊泡的制备方法及其应用 | |
CN114517176A (zh) | 一种将ips细胞诱导成nk细胞的试剂盒及其应用方法 | |
WO2013123607A1 (zh) | 用于成体干细胞的体外无血清培养的方法和培养基 | |
CN112725259A (zh) | 一种干细胞向汗腺样细胞分化的诱导培养基和诱导方法 | |
CN109749981B (zh) | 人源脂肪干细胞来源的肝细胞样细胞及其制备方法和应用 | |
CN111925986A (zh) | 一种脐带间充质干细胞无血清培养基及其制备方法 | |
CN112626012A (zh) | 一种促进干细胞生长的培养液及其制作方法 | |
KR102373196B1 (ko) | 소변 유래 다능성 세포의 대량 증식 방법 | |
KR101633019B1 (ko) | 중간엽 줄기세포로부터 유도만능 줄기세포주의 제조방법 및 수득된 세포주 | |
CN116590235B (zh) | 一种高效的消化道肿瘤类器官培养方法 | |
WO2023113109A1 (ko) | 상하부 구조의 이중 웰을 이용한 지방 유래 줄기세포의 분리 방법 | |
CN115386546A (zh) | 一种脐带间充质干细胞的培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 610000 No. 701, 702, 704, Floor 7, Unit 2, Building 1, No. 818, Xingshi Road, Wuhou District, Chengdu, Sichuan Applicant after: Chengdu nuoyeide medical laboratory Co.,Ltd. Applicant after: Shenzhen Jingke Biotechnology Co.,Ltd. Address before: 610043 No. 701, 702, 704, 7th Floor, Unit 2, Building 1, No. 818, Xingshi Road, Wuhou District, Chengdu, Sichuan Province Applicant before: Chengdu nuoyeide medical laboratory Co.,Ltd. Country or region before: China Applicant before: GUAGNZHOU JINGKE BIOTECH CO.,LTD. |
|
CB02 | Change of applicant information |